2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial

Authors:

Abstract
No abstract available
Funding Information
  • Novartis AG

This publication has 37 references indexed in Scilit: